Data / Drug companies / Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor drugs: 7 drugs from 32 companies in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 40 products in this class from 32 companies, covering 7 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on October 28, 2026.
The request: Get every company that lists a Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor drug in the FDA NDC directory, with headquarters, website and size. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 32Companies
- 40Products
- 7Drugs by generic name
Drugs in the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Valganciclovir | 14 | 14 |
| Valganciclovir hydrochloride | 14 | 11 |
| Ganciclovir sodium | 7 | 5 |
| Ganciclovir | 2 | 2 |
| Cidofovir anhydrous | 1 | 1 |
| Cidofovir dihydrate | 1 | 1 |
| Valganciclovir hydrochloride powder, | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Ajanta Pharma USA Inc. | 2 | tablet; powder, for solution | Generic drugs (ANDA) | January 13, 2020 |
| AvKARE | 2 | powder, for solution; tablet, film coated | Generic drugs (ANDA) | December 21, 2023 |
| Camber Pharmaceuticals, Inc. | 2 | tablet, film coated; powder, for solution | Generic drugs (ANDA) | October 4, 2022 |
| Fresenius Kabi USA, LLC | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 28, 2010 |
| H2-Pharma, LLC | 2 | tablet, film coated; powder, for solution | New drug applications (NDA) | August 28, 2009 |
| NorthStar RxLLC | 2 | powder, for solution; tablet | Generic drugs (ANDA) | March 1, 2026 |
| Slate Run Pharmaceuticals, LLC | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 1, 2019 |
| Strides Pharma Science Limited | 2 | tablet, film coated | Generic drugs (ANDA) | June 16, 2025 |
| Actavis Pharma, Inc. | 1 | powder, for solution | Generic drugs (ANDA) | August 26, 2016 |
| Airis Pharma PVT LTD | 1 | for solution | Generic drugs (ANDA) | February 28, 2022 |
| Alembic Pharmaceuticals Inc. | 1 | powder, for solution | Generic drugs (ANDA) | October 28, 2026 |
| Alembic Pharmaceuticals Limited | 1 | powder, for solution | Generic drugs (ANDA) | October 28, 2026 |
| American Health Packaging | 1 | tablet, film coated | Generic drugs (ANDA) | January 16, 2015 |
| American Health Packaging | 1 | powder, for solution | Generic drugs (ANDA) | August 20, 2023 |
| Aurobindo Pharma Limited | 1 | tablet | Generic drugs (ANDA) | March 31, 2016 |
| Aurobindo Pharma Limited | 1 | for solution | Generic drugs (ANDA) | November 17, 2022 |
| AvPAK | 1 | tablet, film coated | Generic drugs (ANDA) | July 27, 2016 |
| Bausch & Lomb Incorporated | 1 | gel | New drug applications (NDA) | April 30, 2010 |
| Dr. Reddy's Laboratories Inc. | 1 | tablet | Generic drugs (ANDA) | December 12, 2017 |
| Dr. Reddy's Laboratories Limited | 1 | tablet, film coated | Generic drugs (ANDA) | December 15, 2014 |
| Florida Pharmaceutical Products, LLC | 1 | powder, for solution | Generic drugs (ANDA) | July 1, 2023 |
| Granules Pharmaceuticals Inc. | 1 | for solution | Generic drugs (ANDA) | July 1, 2021 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 1 | injection, solution | Generic drugs (ANDA) | August 6, 2012 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 17, 2021 |
| Major Pharmaceuticals | 1 | tablet, film coated | Generic drugs (ANDA) | March 18, 2016 |
| Micro Labs Limited | 1 | powder, for solution | Generic drugs (ANDA) | June 1, 2026 |
| Mylan Institutional LLC | 1 | injection, solution | Generic drugs (ANDA) | June 3, 2013 |
| Novadoz Pharmaceuticals LLC | 1 | for solution | Generic drugs (ANDA) | February 17, 2022 |
| Par Health USA, LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 6, 2016 |
| Pharmascience Inc. | 1 | injection, solution | Generic drugs (ANDA) | April 24, 2018 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | February 15, 2018 |
| Somerset Therapeutics, LLC | 1 | for solution | Generic drugs (ANDA) | January 15, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder, for solution | 11 | 27.5% |
| Tablet, film coated | 9 | 22.5% |
| Injection, powder, lyophilized, for solution | 6 | 15% |
| For solution | 5 | 12.5% |
| Injection, solution | 4 | 10% |
| Tablet | 4 | 10% |
| Gel | 1 | 2.5% |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.